Inflammatory Bowel Disease and Neurodegenerative Diseases

키워드

참고문헌 (90)

1. Chang JT, "Pathophysiology of inflammatory bowel diseases", N Engl J Med, 383, pp.2652~2664 (2020)
2. Walker KA, "Systemic inflammation during midlife and cognitive change over 20 years : the ARIC study", Neurology, 92, pp.e1256~e1267 (2019)
3. Li L, "Risk of multiple sclerosis among users of antitumor necrosis factor alpha in four Canadian provinces : a population-based study", Neurology, 100, pp.e558~e567 (2023)
4. Wang X, "Multiple sclerosis and inflammatory bowel disease : a systematic review and meta-analysis", Ann Clin Transl Neurol, 9, pp.132~140 (2022)
5. Kosmidou M, "Multiple sclerosis and inflammatory bowel diseases : a systematic review and meta-analysis", J Neurol, 264, pp.254~259 (2017)
6. Barberio B, "Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.359~370 (2021)
7. Bisgaard TH, "Depression and anxiety in inflammatory bowel disease : epidemiology, mechanisms and treatment", Nat Rev Gastroenterol Hepatol, 19, pp.717~726 (2022)
8. Marrie RA, "The relationship between symptoms of depression and anxiety and disease activity in IBD over time", Inflamm Bowel Dis, 27, pp.1285~1293 (2021)
9. Villumsen M, "Inflammatory bowel disease increases the risk of Parkinson’s disease : a Danish nationwide cohort study 1977-2014", Gut, 68, pp.18~24 (2019)
10. Peter I, "Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease", JAMA Neurol, 75, pp.939~946 (2018)
11. Zhang B, "Inflammatory bowel disease is associated with higher dementia risk : a nationwide longitudinal study", Gut, 70, pp.85~91 (2021)
12. Aggarwal M, "Alzheimer disease occurs more frequently in patients with inflammatory bowel disease : insight from a nationwide study", J Clin Gastroenterol, 57, pp.501~507 (2023)
13. Kim GH, "Risk of neurodegenerative diseases in patients with inflammatory bowel disease : a nationwide population-based cohort study", J Crohns Colitis, 16, pp.436~443 (2022)
14. Rønnow Sand J, "Risk of dementia in patients with inflammatory bowel disease : a Danish populationbased study", Aliment Pharmacol Ther, 56, pp.831~843 (2022)
15. Sun Y, "Association between inflammatory bowel disease and dementia : a longitudinal cohort study", Inflamm Bowel Dis, 28, pp.1520~1526 (2022)
16. Zezos P, "Inflammatory bowel disease and thromboembolism", World J Gastroenterol, 20, pp.13863~13878 (2014)
17. Mayer EA, "The gut-brain axis", Annu Rev Med, 73, pp.439~453 (2022)
18. Ancona A, "The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease", Dig Liver Dis, 53, pp.298~305 (2021)
19. Margolis KG, "The microbiota-gutbrain axis : from motility to mood", Gastroenterology, 160, pp.1486~1501 (2021)
20. Mittal R, "Neurotransmitters : the critical modulators regulating gut-brain axis", J Cell Physiol, 232, pp.2359~2372 (2017)
21. Günther C, "The gut-brain axis in inflammatory bowel disease-current and future perspectives", Int J Mol Sci, 22, pp.8870~ (2021)
22. Agirman G, "Signaling inflammation across the gut-brain axis", Science, 374, pp.1087~1092 (2021)
23. Bonaz BL, "Brain-gut interactions in inflammatory bowel disease", Gastroenterology, 144, pp.36~49 (2013)
24. Ní Dhonnabháín R, "Aberrant gut-tobrain signaling in irritable bowel syndrome: the role of bile acids", Front Endocrinol(Lausanne), 12, pp.745190~ (2021)
25. Banfi D, "Impact of microbial metabolites on microbiota-gut-brain axis in inflammatory bowel disease", Int J Mol Sci, 22, pp.1623~ (2021)
26. Xiao L, "Gut microbiota-derived metabolites in irritable bowel syndrome", Front Cell Infect Microbiol, 11, pp.729346~ (2021)
27. Zhu Y, "Association between inflammatory bowel diseases and Parkinson’s disease : systematic review and meta-analysis", Neural Regen Res, 17, pp.344~353 (2022)
28. Zhu F, "The risk of Parkinson’s disease in inflammatory bowel disease : a systematic review and meta-analysis", Dig Liver Dis, 51, pp.38~42 (2019)
29. Weimers P, "Inflammatory bowel disease and Parkinson’s disease : a nationwide swedish cohort study", Inflamm Bowel Dis, 25, pp.111~123 (2019)
30. Lin JC, "Association between Parkinson’s disease and inflammatory bowel disease : a nationwide Taiwanese retrospective cohort study", Inflamm Bowel Dis, 22, pp.1049~1055 (2016)
31. Park S, "Patients with inflammatory bowel disease are at an increased risk of Parkinson’s disease : a South Korean nationwide population-based study", J Clin Med, 8, pp.1191~ (2019)
32. Brudek T, "Inflammatory bowel diseases and Parkinson’s disease", J Parkinsons Dis, 9, pp.S331~S344 (2019)
33. Hui KY, "Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease", Sci Transl Med, 10, pp.eaai7795~ (2018)
34. Lee HS, "Inflammatory bowel disease and Parkinson’s disease : common pathophysiological links", Gut, 70, pp.408~417 (2021)
35. Cabezudo D, "Multiple-hit hypothesis in Parkinson’s disease : LRRK2 and inflammation", Front Neurosci, 14, pp.376~ (2020)
36. Li Y, "Intestinal inflammation and Parkinson’s disease", Aging Dis, 12, pp.2052~2068 (2021)
37. Braak H, "Gastric alphasynuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s diseaserelated brain pathology", Neurosci Lett, 396, pp.67~72 (2006)
38. Kim S, "Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease", Neuron, 103, pp.627~641 (2019)
39. Liu B, "Vagotomy and Parkinson disease : a Swedish register-based matched-cohort study", Neurology, 88, pp.1996~2002 (2017)
40. Álvarez-Luquín DD, "Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs : other regulatory populations are also involved", J Neuroinflammation, 16, pp.212~ (2019)
41. Lindqvist D, "Non-motor symptoms in patients with Parkinson’s disease : correlations with inflammatory cytokines in serum", PLoS One, 7, pp.e47387~ (2012)
42. Zhang MN, "The risk of dementia in patients with inflammatory bowel disease : a systematic review and meta-analysis", Int J Colorectal Dis, 37, pp.769~775 (2022)
43. Liu M, "Increased risk for dementia in patients with inflammatory bowel disease : a systematic review and meta-analysis of population-based studies", Front Neurol, 13, pp.813266~ (2022)
44. Zingel R, "Association between inflammatory bowel disease and dementia : a retrospective cohort study", J Alzheimers Dis, 80, pp.1471~1478 (2021)
45. Fousekis FS, "Inflammatory bowel disease and patients with mental disorders : what do we know?", J Clin Med Res, 13, pp.466~473 (2021)
46. Zuin M, "Inflammatory bowel disease as a new risk factor for dementia", Aging Clin Exp Res, 34, pp.1725~1728 (2022)
47. Vadstrup K, "Extraintestinal manifestations and other comorbidities in ulcerative colitis and crohn disease : a Danish nationwide registry study 2003–2016", Crohns Colitis 360, 2, pp.otaa070~ (2020)
48. Guo X, "Letter to the editor : genetically determined IBD is associated with decreased risk of Alzheimer’s disease : a Mendelian randomisation study", Gut, 71, pp.1688~1689 (2022)
49. Wang D, "Inflammatory bowel disease : a potential pathogenic factor of Alzheimer’s disease", Prog Neuropsychopharmacol Biol Psychiatry, 119, pp.110610~ (2022)
50. Sun Y, "Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer’s disease pathology", J Physiol, 598, pp.4209~4223 (2020)
51. Chen C, "Gut inflammation triggers C", EBPβ, EMBO J, pp.2021, 40[DOI]
52. Lloyd-Price J, "Multiomics of the gut microbial ecosystem in inflammatory bowel diseases", Nature, 569, pp.655~662 (2019)
53. Jia W, "Expert insights : the potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer’s disease and hepatic encephalopathy", Med Res Rev, 40, pp.1496~1507 (2020)
54. Mulak A, "Bile acids as key modulators of the brain-gutmicrobiota axis in Alzheimer’s disease", J Alzheimers Dis, 84, pp.461~477 (2021)
55. Xu W, "Meta-analysis of modifiable risk factors for Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 86, pp.1299~1306 (2015)
56. Serrano-Pozo A, "Is Alzheimer’s disease risk modifiable?", J Alzheimers Dis, 67, pp.795~819 (2019)
57. Yuhara H, "Meta-analysis : the risk of venous thromboembolism in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 37, pp.953~962 (2013)
58. Fumery M, "Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases : a meta-analysis of observational studies", J Crohns Colitis, 8, pp.469~479 (2014)
59. Miehsler W, "Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?", Gut, 53, pp.542~548 (2004)
60. Cainzos-Achirica M, "Inflammatory bowel disease and atherosclerotic cardiovascular disease : JACC review topic of the week", J Am Coll Cardiol, 76, pp.2895~2905 (2020)
61. Papa A, "Vascular involvement in inflammatory bowel disease : pathogenesis and clinical aspects", Dig Dis, 26, pp.149~155 (2008)
62. Giannotta M, "Thrombosis in inflammatory bowel diseases : what’s the link?", Thromb J, 13, pp.14~ (2015)
63. Johns DR, "Cerebrovascular complications of inflammatory bowel disease", Am J Gastroenterol, 86, pp.367~370 (1991)
64. Katsanos AH, "Cerebral arterial infarction in inflammatory bowel diseases", Eur J Intern Med, 25, pp.37~44 (2014)
65. Kappelman MD, "Thromboembolic risk among Danish children and adults with inflammatory bowel diseases : a population-based nationwide study", Gut, 60, pp.937~943 (2011)
66. Nguyen GC, "Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients", Am J Gastroenterol, 103, pp.2272~2280 (2008)
67. Ra G, "Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients", J Crohns Colitis, 7, pp.e479~e485 (2013)
68. Scarpa M, "Deep venous thrombosis after surgery for inflammatory bowel disease : is standard dose low molecular weight heparin prophylaxis enough?", World J Surg, 34, pp.1629~1636 (2010)
69. Nguyen GC, "Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting : a decision analysis", Inflamm Bowel Dis, 19, pp.2182~2189 (2013)
70. Zéphir H, "Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease", Mult Scler, 20, pp.1135~1139 (2014)
71. Forbes JD, "The gut microbiota in immune-mediated inflammatory diseases", Front Microbiol, 7, pp.1081~ (2016)
72. Brown J, "Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis", Mult Scler, 27, pp.807~811 (2021)
73. Buscarinu MC, "Intestinal permeability in relapsing-remitting multiple sclerosis", Neurotherapeutics, 15, pp.68~74 (2018)
74. Alkhawajah MM, "Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!", Mult Scler, 19, pp.259~265 (2013)
75. Nouri M, "Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells", PLoS One, 9, pp.e106335~ (2014)
76. Fleck AK, "Gut-CNS-axis as possibility to modulate inflammatory disease activity-implications for multiple sclerosis", Int J Mol Sci, 18, pp.1526~ (2017)
77. Ochoa-Repáraz J, "Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis", J Immunol, 183, pp.6041~6050 (2009)
78. Cantorna MT, "Vitamin D and its role in immunology : multiple sclerosis, and inflammatory bowel disease", Prog Biophys Mol Biol, 92, pp.60~64 (2006)
79. Cantorna MT, "Vitamin D, multiple sclerosis and inflammatory bowel disease", Arch Biochem Biophys, 523, pp.103~106 (2012)
80. Yang Y, "Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases", Nat Commun, 12, pp.5641~ (2021)
81. Gandhi S, "Natural history of new-onset inflammatory bowel disease among patients with multiple sclerosis", Inflamm Bowel Dis, 28, pp.1614~1617 (2022)
82. Pfueller CF, "Multiple sclerosis following etanercept treatment for ankylosing spondylitis", Scand J Rheumatol, 37, pp.397~399 (2008)
83. Casella G, "Neurological disorders and inflammatory bowel diseases", World J Gastroenterol, 20, pp.8764~8782 (2014)
84. Avasarala J, "Use of anti-TNF-αtherapy in Crohn’s disease is associated with increased incidence of multiple sclerosis", Mult Scler Relat Disord, 51, pp.102942~ (2021)
85. Ferro JM, "Neurology of inflammatory bowel disease", J Neurol Sci, 424, pp.117426~ (2021)
86. Peyrin-Biroulet L, "Modulation of sphingosine-1-phosphate in inflammatory bowel disease", Autoimmun Rev, 16, pp.495~503 (2017)
87. Feagan BG, "Ozanimod induction therapy for patients with moderate to severe Crohn’s disease : a single-arm, phase 2, prospective observer-blinded endpoint study", Lancet Gastroenterol Hepatol, 5, pp.819~828 (2020)
88. Sandborn WJ, "Ozanimod as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 385, pp.1280~1291 (2021)
89. Zhang B, "Bidirectional association between inflammatory bowel disease and depression among patients and their unaffected siblings", J Gastroenterol Hepatol, 37, pp.1307~1315 (2022)
90. Sung KY, "Schizophrenia and risk of new-onset inflammatory bowel disease : a nationwide longitudinal study", Aliment Pharmacol Ther, 55, pp.1192~1201 (2022)

관련 논문AI추천